Neuronetics, Inc. announced that Humana has become the first commercial payer to update its policy in response to the Company's recent clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar TMS (transcranial magnetic stimulation) as a first-line add-on for adolescents aged 15-21 with MDD (major depressive disorder). Humana policies cover approximately 600,000 commercial lives in the United States. Prior to the recent policy update, Humana's TMS coverage extended to individuals 18 years and older.

The revision now addresses requests for TMS treatment for adolescents 15-17 years of age as requiring review by a medical director. The effective date for this change was April 25, 2024, only one month after the NeuroStar FDA clearance was announced on March 25, 2024.